Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sara Chisling"'
Autor:
Mark D. Minden, Andrea L. Neumann, Heather M. Duncan, John E. Dick, Kolja Eppert, Isabelle Laverdière, Karin G. Hermans, Sara Chisling
Publikováno v:
Experimental Hematology. 44:S68
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7722f17d812bf6db01313aca85834928
https://doi.org/10.1016/j.exphem.2016.06.120
https://doi.org/10.1016/j.exphem.2016.06.120
Autor:
Amanda Mithchell, Mark D. Minden, John E. Dick, Isabelle Laverdière, Kolja Eppert, Meaghan Boileau, Stanley W.K. Ng, Sara Chisling, Jean C.Y. Wang, Andrea L. Neumann, Heather M. Duncan
Publikováno v:
Blood. 126:3681-3681
Current therapies for acute myeloid leukemia (AML) are able to achieve complete remission in 80-85% of patients; however large portions of these cases relapse. The 5-year survival rate is estimated at 30%. Thus, the development of more efficient appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a7a847258319f69c903c2b449360d1c
https://doi.org/10.1182/blood.v126.23.3681.3681
https://doi.org/10.1182/blood.v126.23.3681.3681
Autor:
Karin G. Hermans, Sara Chisling, Kolja Eppert, Isabelle Laverdière, John E. Dick, Mark D. Minden, Heather M. Duncan
Publikováno v:
Blood. 126:4267-4267
Therapy-resistant leukemic stem cells (LSCs) sustain acute myeloid leukemia (AML) and must be eliminated to cure a patient. However, there are no specific anti-LSC therapies, partially due to poor understanding of the unique molecular biology of thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d4735e670664b9ff3f54c1d6869fc7f
https://doi.org/10.1182/blood.v126.23.4267.4267
https://doi.org/10.1182/blood.v126.23.4267.4267
Autor:
Doucet, Guillaume, Gulli, Roberto A., Corrigan, Benjamin W., Duong, Lyndon R., Martinez‐Trujillo, Julio C.
Publikováno v:
Hippocampus; Mar2020, Vol. 30 Issue 3, p192-209, 18p